我們已在上線！進一步了解

Natera

NTRA

市值 US$567億

393.44 USD

-11.35

2.8%

收盤時已更新 10月16日下午4:00 EDT

盤前交易

盤後交易

393.44

0.00

0%

1天

-2.8%

5天

-2.12%

1個月

13.93%

3個月

45.81%

6個月

100.62%

今年迄今

71.93%

1年

117.92%

5年

253.21%

10年

3,697.68%

關於： Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.

員工： 6,140

醫療保健診斷與研究

新聞

正面

中性

負面

市場情緒 3個月

正面 30%

中性 70%

負面 0%

Natera (NTRA) Price Forecast: Bullish Trend Holds as Next Leg Looms

Natera shares consolidate after a 76% rally, holding key moving-average support as traders watch for a breakout above $437.41 to extend the bullish trend.

Natera (NTRA) Price Forecast: Bullish Trend Holds as Next Leg Looms

Natera's Signatera™ MRD Test Named to TIME's List of the Best Inventions of 2026

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that its Signatera molecular residual disease (MRD) test has been named to TIME's Best Inventions of 2026 list, featuring extraordinary innovations that are changing lives.TIME's Best Inventions list, published annually, highlights the technologies and breakthroughs making the world better, smarter, and more innovative. To compile this year's list, TIME solicited.

Natera's Signatera™ MRD Test Named to TIME's List of the Best Inventions of 2026

Zacks Investment Research

Natera Gains 118.1% in a Year: What's Driving the Rally?

NTRA shares surge 118.1% in a year, fueled by robust Signatera adoption, expanding test volumes and improving margins, despite competition and rising costs.

Natera Gains 118.1% in a Year: What's Driving the Rally?

Natera and TransCode Therapeutics to Collaborate on Phase 2a Trial of TTX-MC138 in Colorectal Cancer

AUSTIN, Texas, & BOSTON--(BUSINESS WIRE)--Natera, Inc. (Nasdaq: NTRA), a global leader in cell-free DNA and precision medicine, and TransCode Therapeutics, Inc. (Nasdaq: RNAZ), a clinical stage company pioneering immuno-oncology and RNA-based therapeutics for the treatment of high-risk and advanced cancers, today announced a strategic collaboration in colorectal cancer (CRC). The collaboration will support enrollment for TransCode's Phase 2a trial evaluating TTX-MC138 in patients with CRC. Pati.

Natera and TransCode Therapeutics to Collaborate on Phase 2a Trial of TTX-MC138 in Colorectal Cancer

FDA Grants Breakthrough Device Designation for Natera's Multi-Cancer Early Detection Assay

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that its multi-cancer early detection (MCED) assay has been granted Breakthrough Device designation (BDD) by the U.S. Food and Drug Administration (FDA). The BDD is designed for novel technologies that enable more effective diagnosis or treatment of life-threatening or irreversibly debilitating diseases or conditions. Natera's MCED assay analyzes cell-free DNA in.

FDA Grants Breakthrough Device Designation for Natera's Multi-Cancer Early Detection Assay

Natera Announces Randomized, Signatera™-Guided Interventional Study in Melanoma

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the enrollment of the first patients in a new Signatera-guided trial in melanoma (NCT07504796), sponsored by NYU Langone Health. The study uses Signatera to guide treatment escalation for patients with advanced or metastatic melanoma, an aggressive form of skin cancer. The current standard of care for these patients is combination immunotherapy until clinical pro.

Natera Announces Randomized, Signatera™-Guided Interventional Study in Melanoma

New Signatera™ Data Presented at ASTRO Conference, Highlights Utility for Radiation Oncologists

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced new data recently shared at the American Society for Radiation Oncology (ASTRO) 2026 Annual Meeting. The presentations marked Natera's first participation at ASTRO and a significant step in demonstrating Signatera's role in treatment response monitoring and risk stratification. All four abstracts were selected for oral presentations, reflecting the breadth of tum.

New Signatera™ Data Presented at ASTRO Conference, Highlights Utility for Radiation Oncologists

Alliance Foundation Trials and Natera Announce AFT-70 NAVIGATE: a Global, Randomized, Phase III Trial Evaluating Genentech's Oral Selective Estrogen Receptor Degrader (SERD) with Signatera™ MRD-Guided CDK4/6 Inhibitor Therapy in Breast Cancer

BOSTON & AUSTIN, Texas--(BUSINESS WIRE)--Alliance Foundation Trials, LLC (AFT), a national leader in conducting innovative, practice-changing cancer clinical trials, and Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the launch of AFT-70 NAVIGATE, a randomized phase III trial evaluating a novel molecular residual disease (MRD)-guided treatment strategy for patients with intermediate and high-risk ER-positive/HER2-negative early breast cance.

Alliance Foundation Trials and Natera Announce AFT-70 NAVIGATE: a Global, Randomized, Phase III Trial Evaluating Genentech's Oral Selective Estrogen Receptor Degrader (SERD) with Signatera™ MRD-Guided CDK4/6 Inhibitor Therapy in Breast Cancer

The Top HealthTech Questions Landing on Our Desks

Strong performance across the healthtech sector over the past two quarters has sparked renewed market interest in medical innovation. Given the volume of inquiries landing on our desks, we compiled this guide to answer a mix of the most frequent and most interesting questions we have received regarding our Healthcare Technology and Innovation Index (HTEC).

The Top HealthTech Questions Landing on Our Desks

Natera, UnitedHealth Group And A Tech Stock On CNBC's ‘Final Trades'

On CNBC's “Halftime Report Final Trades,” Rob Sechan, CEO of NewEdge Wealth, picked Hewlett Packard Enterprise Company (NYSE:HPE).

Natera, UnitedHealth Group And A Tech Stock On CNBC's ‘Final Trades'

查看新聞排名

價格圖表採用Lightweight Charts™實作